{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:08:25Z","timestamp":1787022505638,"version":"build-2736575974"},"reference-count":57,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiovascular diseases (CVD) continue to be the main cause of death in our country. Adequate control of lipid metabolism disorders is a key challenge in cardiovascular prevention that is far from being achieved in real clinical practice. There is a great heterogeneity in the reports of lipid metabolism from Spanish clinical laboratories, which may contribute to its poor control. For this reason, a working group of the main scientific societies involved in the care of patients at vascular risk, has prepared this document with a\u00a0consensus proposal on the determination of the basic lipid profile in cardiovascular prevention, recommendations for its realization and unification of criteria to incorporate the\u00a0lipid control goals appropriate to the vascular risk of the\u00a0patients in the laboratory reports.<\/jats:p>","DOI":"10.1515\/almed-2023-0047","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T01:59:45Z","timestamp":1685930385000},"page":"138-146","source":"Crossref","is-referenced-by-count":3,"title":["Consensus document for lipid profile testing and reporting in Spanish clinical laboratories: what parameters should a basic lipid profile include?"],"prefix":"10.1515","volume":"4","author":[{"given":"Teresa","family":"Arrobas Velilla","sequence":"first","affiliation":[{"name":"Spanish Society of Laboratory Medicine (SEQCML), Laboratory of Clinical Biochemistry , Virgen Macarena University Hospital , Seville , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Guijarro","sequence":"additional","affiliation":[{"name":"Spanish Society of Arteriosclerosis (SEA), Unit of Internal Medicine , Hospital Alcorc\u00f3n Foundation University Hospital, Rey Juan Carlos University , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Campuzano","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Spanish Society of Cardiology (SEC), Unit of Cardiology , Alcorc\u00f3n Foundation University Hospital, Association for Vascular Risk and Cardiac Rehabilitation of the Spanish Society of Cardiology , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Rodr\u00edguez","family":"Pi\u00f1ero","sequence":"additional","affiliation":[{"name":"Spanish Society of Angiology and Vascular Surgery (SEACV), Cross-center C\u00e1diz-Jerez Unit of Angiology and Vascular Surgery , Puerta del Mar University Hospital , C\u00e1diz , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Francisco","family":"Valderrama Marcos","sequence":"additional","affiliation":[{"name":"Spanish Society of Cardiovascular and Endovascular Surgery , Cardiovascular Surgery (SECCE), Regional University Hospital of Malaga , M\u00e1laga , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e9rez P\u00e9rez","sequence":"additional","affiliation":[{"name":"Spanish Society of Diabetes (SED) , Endocrinology and Nutrition Department , Hospital de la Santa Creu i Sant Pau , Barcelona , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio M.","family":"Botana L\u00f3pez","sequence":"additional","affiliation":[{"name":"Spanish Society of Endocrinology and Nutrition (SEEN), Section of Endocrinology , Lucus Augusti University Hospital , Lugo , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Morais","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Spanish Society of Gastroenterology, Paediatric Hepatology and Nutrition (SEGHNP), Unit of Paediatric Nutrition and Metabolic Diseases , La Paz University Hospital , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Garc\u00eda Donaire","sequence":"additional","affiliation":[{"name":"Spanish Society of Hypertension, Spanish League for the Fight Against Arterial Hypertension (SEH-LELHA), Unit of Arterial Hypertension , Hospital Cl\u00ednico Universitario San Carlos , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Obaya","sequence":"additional","affiliation":[{"name":"Spanish Society of Family and Community Family (SEMFyC) , CS La Chopera, Alcobendas , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Castilla-Guerra","sequence":"additional","affiliation":[{"name":"Spanish Society of Internal Medicine (SEMI), Unit of Hypertension, Lipids and Vascular Risk , Service of Internal Medicine , Seville , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente Pallares","family":"Carratal\u00e1","sequence":"additional","affiliation":[{"name":"Hospital Virgen Macarena, PCDV Departamento de Medicina , University of Seville , Sevilla , Spain"},{"name":"Spanish Society of Primary Care Physicians (SEMERGEN), Unit of Health Surveillance, Uni\u00f3n de Mutuas, Department of Medicine , Universitat Jaume I, Castell\u00f3n , Castell\u00f3n , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel Egocheaga","family":"Cabello","sequence":"additional","affiliation":[{"name":"Spanish Society of General and Family Doctors (SEMG), Family and Community Medicine , Centro de Salud Isla de Oza, Servicio Madrile\u00f1o de Salud , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes Salgueira","family":"Lazo","sequence":"additional","affiliation":[{"name":"Spanish Society of Nephrology (SEN), Unit of Nephrology , Virgen Macarena University Hospital , Seville , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Mar","family":"Castellanos Rodrigo","sequence":"additional","affiliation":[{"name":"Spanish Society of Neurology (SEN), Service of Neurology , Complejo Hospitalario Universitario A Coru\u00f1a\/Instituto de Investigaci\u00f3n Biom\u00e9dica A Coru\u00f1a , Coru\u00f1a , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Mostaza Prieto","sequence":"additional","affiliation":[{"name":"Spanish Society of Arteriosclerosis (SEA), Service of Internal Medicine , Hospital La Paz-Carlos III , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"G\u00f3mez Doblas","sequence":"additional","affiliation":[{"name":"Spanish Society of Cardiology (SEC), Service of Cardiology , Virgen de la Victoria University Hospital , M\u00e1laga , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bu\u00f1o Soto","sequence":"additional","affiliation":[{"name":"Spanish Society of Laboratory Medicine (SEQCML), Service of Clinical Biochemistry , La Paz University Hospital , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"2024040320203867824_j_almed-2023-0047_ref_001","doi-asserted-by":"crossref","unstructured":"Roth, GA, Abate, D, Abate, KH, Abay, SM, Abbafati, C, Abbasi, N, et al.. GBD 2017 Causes of Death Collaborators Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Lond Engl 2018;392:1736\u201388. https:\/\/doi.org\/10.1016\/S0140-6736(18)32203-7.","DOI":"10.1016\/S0140-6736(18)32203-7"},{"key":"2024040320203867824_j_almed-2023-0047_ref_002","unstructured":"INE Defunciones por causas (lista reducida) por sexo y grupos de edad(7947). INE Available from: https:\/\/www.ine.es\/jaxiT3\/Datos.htm?t=7947#!tabs-tabla [accedido 16 febrero 2022]."},{"key":"2024040320203867824_j_almed-2023-0047_ref_003","doi-asserted-by":"crossref","unstructured":"Bor\u00e9n, J, Chapman, MJ, Krauss, RM, Packard, CJ, Bentzon, JF, Binder, CJ, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2020;41:2313\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehz962.","DOI":"10.1093\/eurheartj\/ehz962"},{"key":"2024040320203867824_j_almed-2023-0047_ref_004","doi-asserted-by":"crossref","unstructured":"Royo Bordonada, M\u00c1, Lobos Bejarano, JM, Mill\u00e1n N\u00fa\u00f1ez-Cort\u00e9s, J, Villar \u00c1lvarez, F, Brotons Cuixart, C, Camafort Babkowski, M, et al.. Dislipidemias: un reto pendiente en prevenci\u00f3n cardiovascular. Documento de consenso CEIPC\/SEA. Med Cl\u00ednica 2011;137:30.e1\u201313, https:\/\/doi.org\/10.1016\/j.medcli.2011.02.008.","DOI":"10.1016\/j.medcli.2011.02.008"},{"key":"2024040320203867824_j_almed-2023-0047_ref_005","doi-asserted-by":"crossref","unstructured":"De Backer, G, Jankowski, P, Kotseva, K, Mirrakhimov, E, Reiner, \u017d, Ryd\u00e9n, L, et al.. Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis 2019;285:135\u201346. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.03.014.","DOI":"10.1016\/j.atherosclerosis.2019.03.014"},{"key":"2024040320203867824_j_almed-2023-0047_ref_006","doi-asserted-by":"crossref","unstructured":"Ray, KK, Molemans, B, Schoonen, WM, Giovas, P, Bray, S, Kiru, G, et al.. EU-wide cross- sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 2021;28:1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","DOI":"10.1093\/eurjpc\/zwaa047"},{"key":"2024040320203867824_j_almed-2023-0047_ref_007","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Juanatey, JR, Mill\u00e1n, J, Alegr\u00eda, E, Guijarro, C, Lozano, JV, Vitale, GC. Prevalence and characteristics of lipid abnormalities in patients treated with statins in primary and secondary prevention in Spain. DYSIS-Spain study. Rev Esp Cardiol Engl Ed 2011;64:286\u201394. https:\/\/doi.org\/10.1016\/j.rec.2010.10.030.","DOI":"10.1016\/j.rec.2010.10.030"},{"key":"2024040320203867824_j_almed-2023-0047_ref_008","doi-asserted-by":"crossref","unstructured":"Robinson, JG, Huijgen, R, Ray, K, Persons, J, Kastelein, JJP, Pencina, MJ. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol 2016;68:2412\u201321. https:\/\/doi.org\/10.1016\/j.jacc.2016.09.928.","DOI":"10.1016\/j.jacc.2016.09.928"},{"key":"2024040320203867824_j_almed-2023-0047_ref_009","doi-asserted-by":"crossref","unstructured":"Visseren, FLJ, Mach, F, Smulders, YM, Carballo, D, Koskinas, KC, B\u00e4ck, M, et al.. ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J 2021;42:3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","DOI":"10.1093\/eurheartj\/ehab484"},{"key":"2024040320203867824_j_almed-2023-0047_ref_010","doi-asserted-by":"crossref","unstructured":"Visseren, LJF, Mach, F, Smulders, MY, Carballo, D, Koskinas, CK, B\u00e4ck, M, et al.. Gu\u00eda ESC 2021 sobre la prevenci\u00f3n de la enfermedad cardiovascular en la pr\u00e1ctica cl\u00ednica: con la contribuci\u00f3n especial de la European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol 2022;75:429.e1\u2013104. https:\/\/doi.org\/10.1016\/j.recesp.2021.10.016.","DOI":"10.1016\/j.recesp.2021.10.015"},{"key":"2024040320203867824_j_almed-2023-0047_ref_011","doi-asserted-by":"crossref","unstructured":"Palacio-Portilla, EJ, Roquer, J, Amaro, S, Arenillas, JF, Ayo-Mart\u00edn, O, Castellanos, M, et al.. Dislipidemias y prevenci\u00f3n del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Espa\u00f1ola de Neurolog\u00eda. Neurolog\u00eda. 2022;37:61\u201372. https:\/\/doi.org\/10.1016\/j.nrl.2020.07.027.","DOI":"10.1016\/j.nrl.2020.07.027"},{"key":"2024040320203867824_j_almed-2023-0047_ref_012","doi-asserted-by":"crossref","unstructured":"Mostaza, JM, Pint\u00f3, X, Armario, P, Masana, L, Real, JT, Valdivielso, P, et al.. Est\u00e1ndares SEA 2022 para el control global del riesgo cardiovascular. Cl\u00ednica E Investig En Arterioscler 2022;34:130\u201379. https:\/\/doi.org\/10.1016\/j.arteri.2021.11.003.","DOI":"10.1016\/j.arteri.2021.11.003"},{"key":"2024040320203867824_j_almed-2023-0047_ref_013","doi-asserted-by":"crossref","unstructured":"Armario, P, Brotons, C, Elosua, R, Alonso de Leci\u00f1ana, M, Castro, A, Clar\u00e0, A, et al.. Statement of the Spanish interdisciplinary vascular prevention committee on the updated European cardiovascular prevention guidelines. Clin E Investig En Arterioscler Publicacion Soc Espanola Arterioscler 2021;33:85\u2013107. https:\/\/doi.org\/10.1016\/j.arteri.2020.11.004.","DOI":"10.1016\/j.artere.2021.02.001"},{"key":"2024040320203867824_j_almed-2023-0047_ref_014","doi-asserted-by":"crossref","unstructured":"Pedro-Botet, J, Rodr\u00edguez-Padial, L, Brotons, C, Esteban-Sal\u00e1n, M, Garc\u00eda-Ler\u00edn, A, Pint\u00f3, X, et al.. Homogeneizaci\u00f3n de los valores del perfil lip\u00eddico. Cl\u00ednica E Investig En Arterioscler 2018;30:36\u201348. https:\/\/doi.org\/10.1016\/j.arteri.2017.12.001.","DOI":"10.1016\/j.arteri.2017.12.001"},{"key":"2024040320203867824_j_almed-2023-0047_ref_015","doi-asserted-by":"crossref","unstructured":"Pedro-Botet, J, Rodr\u00edguez-Padial, L, Brotons, C, Esteban-Sal\u00e1n, M, Garc\u00eda-Ler\u00edn, A, Pint\u00f3, X, et al.. El informe anal\u00edtico ideal del perfil lip\u00eddico. Necesidad de un consenso. Rev Esp Cardiol 2018;71:512\u20134. https:\/\/doi.org\/10.1016\/j.recesp.2018.01.004.","DOI":"10.1016\/j.recesp.2018.01.004"},{"key":"2024040320203867824_j_almed-2023-0047_ref_016","doi-asserted-by":"crossref","unstructured":"Wright, IS. Correct levels of serum cholesterol: average vs. normal vs. optimal. J Am Med Assoc 1976;236:261\u20132. https:\/\/doi.org\/10.1001\/jama.1976.03270030015018.","DOI":"10.1001\/jama.236.3.261"},{"key":"2024040320203867824_j_almed-2023-0047_ref_036","doi-asserted-by":"crossref","unstructured":"Mach, F, Baigent, C, Catapano, AL, Koskinas, KC, Casula, M, Badimon, L, et al.. ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"2024040320203867824_j_almed-2023-0047_ref_019","doi-asserted-by":"crossref","unstructured":"Cooper, GR, Myers, GL, Smith, SJ, Schlant, RC. Blood lipid measurements: variations and practical utility. J Am Med Assoc 1992;267:1652\u201360. https:\/\/doi.org\/10.1001\/jama.1992.03480120090039.","DOI":"10.1001\/jama.267.12.1652"},{"key":"2024040320203867824_j_almed-2023-0047_ref_020","doi-asserted-by":"crossref","unstructured":"Bays, HE, Jones, PH, Orringer, CE, Brown, WV, Jacobson, TA. National lipid association annual summary of clinical lipidology 2016. J Clin Lipidol. 2016;10:S1-43, https:\/\/doi.org\/10.1016\/j.jacl.2015.08.002.","DOI":"10.1016\/j.jacl.2015.08.002"},{"key":"2024040320203867824_j_almed-2023-0047_ref_021","unstructured":"Herink, M, Ito, MK. Medication induced changes in lipid and lipoproteins. In: Feingold, KR, Anawalt, B, Boyce, A, Chrousos, G, de, Herder WW, Dhatariya, K, et al.. editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000."},{"key":"2024040320203867824_j_almed-2023-0047_ref_022","doi-asserted-by":"crossref","unstructured":"Khovidhunkit, W, Kim, M-S, Memon, RA, Shigenaga, JK, Moser, AH, Feingold, KR, et al.. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004;45:1169\u201396. https:\/\/doi.org\/10.1194\/jlr.R300019-JLR200.","DOI":"10.1194\/jlr.R300019-JLR200"},{"key":"2024040320203867824_j_almed-2023-0047_ref_023","unstructured":"Feingold, KR, Grunfeld, C. The effect of inflammation and infection on lipids and lipoproteins. In: Feingold, KR, Anawalt, B, Boyce, Ade, Herder WW Dhatariya, K, et al.. editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000."},{"key":"2024040320203867824_j_almed-2023-0047_ref_024","doi-asserted-by":"crossref","unstructured":"van Leeuwen, HJ, Heezius, ECJM, Dallinga, GM, van Strijp, JAG, Verhoef, J, van Kessel, KPM. Lipoprotein metabolism in patients with severe sepsis. Crit Care Med 2003;31:1359\u201366. https:\/\/doi.org\/10.1097\/01.CCM.0000059724.08290.51.","DOI":"10.1097\/01.CCM.0000059724.08290.51"},{"key":"2024040320203867824_j_almed-2023-0047_ref_025","doi-asserted-by":"crossref","unstructured":"P\u00e1ez-Guill\u00e1n, E-M, Campos-Franco, J, Alende, R, Garitaonaind\u00eda, Y, Gonz\u00e1lez-Quintela, A. Transient hypertriglyceridemia: a common finding during Epstein-Barr virus-induced infectious mononucleosis. Lipids Health Dis 2021;20:177. https:\/\/doi.org\/10.1186\/s12944-021-01603-9.","DOI":"10.1186\/s12944-021-01603-9"},{"key":"2024040320203867824_j_almed-2023-0047_ref_026","unstructured":"Shrivastava, AK, Singh, HV, Raizada, A, Singh, SK. Serial measurement of lipid profile and inflammatory markers in patients with acute myocardial infarction. EXCLI J 2015;14:517\u201326. https:\/\/doi.org\/10.17179\/excli2014-671."},{"key":"2024040320203867824_j_almed-2023-0047_ref_027","doi-asserted-by":"crossref","unstructured":"Wattanasuwan, N, Khan, IA, Gowda, RM, Vasavada, BC, Sacchi, TJ. Effect of acute myocardial infarction on cholesterol ratios. Chest 2001;120:1196\u20139. https:\/\/doi.org\/10.1378\/chest.120.4.1196.","DOI":"10.1378\/chest.120.4.1196"},{"key":"2024040320203867824_j_almed-2023-0047_ref_028","doi-asserted-by":"crossref","unstructured":"Rosenson, RS. Myocardial injury: the acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993;22:933\u201340. https:\/\/doi.org\/10.1016\/0735-1097(93)90213-k.","DOI":"10.1016\/0735-1097(93)90213-K"},{"key":"2024040320203867824_j_almed-2023-0047_ref_029","doi-asserted-by":"crossref","unstructured":"Enkhmaa, B, Anuurad, E, Berglund, L. Lipoprotein (a): impact by thnicity and environmental and medical conditions. J Lipid Res 2016;57:1111\u201325. https:\/\/doi.org\/10.1194\/jlr.R051904.","DOI":"10.1194\/jlr.R051904"},{"key":"2024040320203867824_j_almed-2023-0047_ref_030","doi-asserted-by":"crossref","unstructured":"Langsted, A, Kamstrup, PR, Nordestgaard, BG. Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk. Atherosclerosis 2014;234:95\u2013101. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2014.01.049.","DOI":"10.1016\/j.atherosclerosis.2014.01.049"},{"key":"2024040320203867824_j_almed-2023-0047_ref_031","doi-asserted-by":"crossref","unstructured":"Nordestgaard, BG, Langsted, A, Mora, S, Kolovou, G, Baum, H, Bruckert, E, et al.. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points\u2014a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016;37:1944\u201358. https:\/\/doi.org\/10.1093\/eurheartj\/ehw152.","DOI":"10.1093\/eurheartj\/ehw152"},{"key":"2024040320203867824_j_almed-2023-0047_ref_032","doi-asserted-by":"crossref","unstructured":"Mora, S, Rifai, N, Buring, JE, Ridker, PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008;118:993\u20131001. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.777334.","DOI":"10.1161\/CIRCULATIONAHA.108.777334"},{"key":"2024040320203867824_j_almed-2023-0047_ref_033","doi-asserted-by":"crossref","unstructured":"Martin, SS, Blaha, MJ, Elshazly, MB, Toth, PP, Kwiterovich, PO, Blumenthal, RS, et al.. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. J Am Med Assoc 2013;310:2061\u20138. https:\/\/doi.org\/10.1001\/jama.2013.280532.","DOI":"10.1001\/jama.2013.280532"},{"key":"2024040320203867824_j_almed-2023-0047_ref_018","doi-asserted-by":"crossref","unstructured":"Wilson, PWF, Jacobson, TA, Martin, SS, Jackson, EJ, Le, N-A, Davidson, MH, et al.. Lipid measurements in the management of cardiovascular diseases: practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol 2021;15:629\u201348. https:\/\/doi.org\/10.1016\/j.jacl.2021.09.046.","DOI":"10.1016\/j.jacl.2021.09.046"},{"key":"2024040320203867824_j_almed-2023-0047_ref_034","doi-asserted-by":"crossref","unstructured":"Martin, SS, Blaha, MJ, Elshazly, MB, Brinton, EA, Toth, PP, McEvoy, JW, et al.. Friedewald- estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol 2013;62:732\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2013.01.079.","DOI":"10.1016\/j.jacc.2013.01.079"},{"key":"2024040320203867824_j_almed-2023-0047_ref_035","doi-asserted-by":"crossref","unstructured":"Sniderman, AD, Williams, K, Contois, JH, Monroe, HM, McQueen, MJ, De Graaf, J, et al.. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b as markers of cardiovascular risk. Circ Cardiovasc Qual OuTgomes 2011;4:337\u201345. https:\/\/doi.org\/10.1161\/CIRCOUTgOMES.110.959247.","DOI":"10.1161\/CIRCOUTCOMES.110.959247"},{"key":"2024040320203867824_j_almed-2023-0047_ref_017","doi-asserted-by":"crossref","unstructured":"Nordestgaard, BG, Langlois, MR, Langsted, A, Chapman, MJ, Aakre, KM, Baum, H, et al.. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Atherosclerosis 2020;294:46\u201361. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.12.005.","DOI":"10.1016\/j.atherosclerosis.2019.12.005"},{"key":"2024040320203867824_j_almed-2023-0047_ref_037","doi-asserted-by":"crossref","unstructured":"Arnett, DK, Blumenthal, RS, Albert, MA, Buroker, AB, Goldberger, ZD, Hahn, EJ, et al.. ACC\/AHA guideline on the primary prevention of cardiovascular disease. Circulation 2019;140:e596-600.","DOI":"10.1161\/CIR.0000000000000677"},{"key":"2024040320203867824_j_almed-2023-0047_ref_038","doi-asserted-by":"crossref","unstructured":"Grundy, SM, Stone, NJ, Bailey, AL, Beam, C, BirTgher, KK, Blumenthal, RS, et al.. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American college of Cardiology\/American heart association Task Force on clinical practice guidelines. Circulation 2019;139:e1082\u2013143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625.","DOI":"10.1161\/CIR.0000000000000698"},{"key":"2024040320203867824_j_almed-2023-0047_ref_039","doi-asserted-by":"crossref","unstructured":"Pearson, GJ, Thanassoulis, G, Anderson, TJ, Barry, AR, Couture, P, Dayan, N, et al.. Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Can J Cardiol 2021;S0828\u2013282X:00165\u20133. https:\/\/doi.org\/10.1016\/j.cjca.2021.03.016.","DOI":"10.1016\/j.cjca.2021.03.016"},{"key":"2024040320203867824_j_almed-2023-0047_ref_040","doi-asserted-by":"crossref","unstructured":"Langlois, MR, Nordestgaard, BG, Langsted, A, Chapman, MJ, Aakre, KM, Baum, H, et al.. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Clin Chem Lab Med 2020;58:496\u2013517. https:\/\/doi.org\/10.1515\/cclm-2019-1253.","DOI":"10.1515\/cclm-2019-1253"},{"key":"2024040320203867824_j_almed-2023-0047_ref_041","doi-asserted-by":"crossref","unstructured":"Marston, NA, Giugliano, RP, Melloni, GEM, Park, J-G, Morrill, V, Blazing, MA, et al.. Association of apolipoprotein B\u2013containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiol 2022;7:250\u20136. https:\/\/doi.org\/10.1001\/jamacardio.2021.5083.","DOI":"10.1001\/jamacardio.2021.5083"},{"key":"2024040320203867824_j_almed-2023-0047_ref_042","doi-asserted-by":"crossref","unstructured":"SCORE2 working group and ESC Cardiovascular risk collaboration SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439\u201354, https:\/\/doi.org\/10.1093\/eurheartj\/ehab309.","DOI":"10.1093\/eurheartj\/ehab309"},{"key":"2024040320203867824_j_almed-2023-0047_ref_043","doi-asserted-by":"crossref","unstructured":"SCORE2-OP working group and ESC Cardiovascular risk collaboration SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42:2455\u201367, https:\/\/doi.org\/10.1093\/eurheartj\/ehab312.","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"2024040320203867824_j_almed-2023-0047_ref_044","doi-asserted-by":"crossref","unstructured":"Di Angelantonio, E, Sarwar, N, Perry, P, Kaptoge, S, Ray, KK, Thompson, A, et al., Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. J Am Med Assoc 2009;302:1993\u20132000. https:\/\/doi.org\/10.1001\/jama.2009.1619.","DOI":"10.1001\/jama.2009.1619"},{"key":"2024040320203867824_j_almed-2023-0047_ref_045","doi-asserted-by":"crossref","unstructured":"Richardson, T, Sanderson, E, Palmer, TM, Ala-Korpela, M, Ference, BA, Davey Smith, G, et al.. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. Plos Med 2020;17. https:\/\/doi.org\/10.1371\/journal.pmed.1003062.","DOI":"10.1371\/journal.pmed.1003062"},{"key":"2024040320203867824_j_almed-2023-0047_ref_046","doi-asserted-by":"crossref","unstructured":"Pint\u00f3, X, Masana, L, Civeira, F, Real, J, Ibarretxe, D, Candas, B, et al.. Consensus document of an expert group from the Spanish Society of Arteriosclerosis (SEA) on the clinical use of nuclear magnetic resonance to assess lipoprotein metabolism (Liposcale\u00ae). Clin E Investig En Arterioscler Publicacion Of Soc Espanola Arterioscler 2020;32:219\u201329. https:\/\/doi.org\/10.1016\/j.arteri.2020.04.004.","DOI":"10.1016\/j.artere.2020.04.001"},{"key":"2024040320203867824_j_almed-2023-0047_ref_047","unstructured":"WHO Human Genetics Programme Familial hypercholesterolaemia (FH) : report of a second WHO consultation, Geneva: World Health Organization; 1999."},{"key":"2024040320203867824_j_almed-2023-0047_ref_048","doi-asserted-by":"crossref","unstructured":"Paquette, M, Bernard, S, Blank, D, Par\u00e9, G, Baass, A. A simplified diagnosis algorithm for dysbetalipoproteinemia. J Clin Lipidol 2020;14:431\u20137. https:\/\/doi.org\/10.1016\/j.jacl.2020.06.004.","DOI":"10.1016\/j.jacl.2020.06.004"},{"key":"2024040320203867824_j_almed-2023-0047_ref_049","doi-asserted-by":"crossref","unstructured":"Wilson, DP, Jacobson, TA, Jones, PH, Koschinsky, ML, McNeal, CJ, Nordestgaard, BG, et al.. Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association. J Clin Lipidol 2019;13:374\u201392. https:\/\/doi.org\/10.1016\/j.jacl.2019.04.010.","DOI":"10.1016\/j.jacl.2019.04.010"},{"key":"2024040320203867824_j_almed-2023-0047_ref_050","doi-asserted-by":"crossref","unstructured":"Reyes-Soffer, G, Ginsberg, HN, Berglund, L, Duell, PB, Heffron, SP, Kamstrup, PR, et al.. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol 2021;42:e48-60. https:\/\/doi.org\/10.1161\/ATV.0000000000000147.","DOI":"10.1161\/ATV.0000000000000147"},{"key":"2024040320203867824_j_almed-2023-0047_ref_051","doi-asserted-by":"crossref","unstructured":"Cegla, J, Neely, RDG, France, M, Ferns, G, Byrne, CD, Halcox, J, et al.. HEART UK consensus statement on Lipoprotein(a): a call to action. Atherosclerosis 2019;291:62\u201370. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.10.011.","DOI":"10.1016\/j.atherosclerosis.2019.10.011"},{"key":"2024040320203867824_j_almed-2023-0047_ref_052","doi-asserted-by":"crossref","unstructured":"Kronenberg, F, Mora, S, Stroes, ESG, Ference, BA, Arsenault, BJ, Berglund, L, et al.. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43:3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"2024040320203867824_j_almed-2023-0047_ref_053","doi-asserted-by":"crossref","unstructured":"Burgess, S, Ference, BA, Staley, JR, Freitag, DF, Mason, AM, Nielsen, SF, et al.. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)- lowering therapies: a mendelian randomization analysis. JAMA Cardiol 2018;3:619\u201327. https:\/\/doi.org\/10.1001\/jamacardio.2018.1470.","DOI":"10.1001\/jamacardio.2018.1470"},{"key":"2024040320203867824_j_almed-2023-0047_ref_054","doi-asserted-by":"crossref","unstructured":"Langsted, A, Kamstrup, PR, Benn, M, Tybj\u00e6rg-Hansen, A, Nordestgaard, BG. High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study. Lancet Diabetes Endocrinol 2016;4:577\u201387. https:\/\/doi.org\/10.1016\/S2213-8587(16)30042-0.","DOI":"10.1016\/S2213-8587(16)30042-0"},{"key":"2024040320203867824_j_almed-2023-0047_ref_055","doi-asserted-by":"crossref","unstructured":"Ascaso, JF, Civeira, F, Guijarro, C, L\u00f3pez Miranda, J, Masana, L, Mostaza, JM, et al.. Indicaciones de los inhibidores de proprote\u00edna convertasa subtilisina kexina 9 (PCSK9) en la pr\u00e1ctica cl\u00ednica. Recomendaciones de la Spanish Society of Arteriosclerosis (SEA) 2019. Clin E Investig En Arterioscler Publicacion Of Soc Espanola Arterioscler 2019;31:128\u201339. https:\/\/doi.org\/10.1016\/j.arteri.2019.04.002.","DOI":"10.1016\/j.arteri.2019.04.002"},{"key":"2024040320203867824_j_almed-2023-0047_ref_056","doi-asserted-by":"crossref","unstructured":"Conrad, N, Verbeke, G, Molenberghs, G, Goetschalckx, L, Callender, T, Cambridge, G, et al.. Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet 2022;400:733\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(22)01349-6.","DOI":"10.1016\/S0140-6736(22)01349-6"},{"key":"2024040320203867824_j_almed-2023-0047_ref_057","doi-asserted-by":"crossref","unstructured":"Moulin, P, Dufour, R, Averna, M, Arca, M, Cefal\u00f9, AB, Noto, D, et al.. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an \u00abFCS score\u00bb. Atherosclerosis 2018;275:265\u201372. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.06.814.","DOI":"10.1016\/j.atherosclerosis.2018.06.814"}],"container-title":["Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2023-0047\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2023-0047\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T16:21:51Z","timestamp":1712161311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/almed-2023-0047\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,1]]},"references-count":57,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,5,30]]},"published-print":{"date-parts":[[2023,6,12]]}},"alternative-id":["10.1515\/almed-2023-0047"],"URL":"https:\/\/doi.org\/10.1515\/almed-2023-0047","relation":{},"ISSN":["2628-491X"],"issn-type":[{"value":"2628-491X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,1]]}}}